Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03335072 · ClinicalTrials.gov registry record · Phase 4

Kebele Elimination of Trachoma for Ocular Health

A Phase 4 study of Trachoma, sponsored by University of California, San Francisco.

Active
Registry status
Phase 4
Development phase
320,000
Enrollment target
2
Study locations

NCT03335072 is a Phase 4 study of Trachoma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 320,000 participants, above the 565-participant average among 4 other Trachoma trials with a reported enrollment target (56537% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03335072, a Phase 4 study of Trachoma, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
320,000 participants
Enrollment target
2
Study locations

Study Summary

The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution.

Conditions Studied

Interventions

  • DRUG Azithromycin

Study Locations (2)

California

  • UCSF Proctor Foundation - San Francisco

Other

  • Eyu-Ethiopia - Bahir Dar

Trial Details

FieldValue
Enrollment Target 320,000 participants
Start Date 2022-02-07
Est. Completion 2028-03-01
Phase Phase 4

What the Registry Record Tells You About NCT03335072

The ClinicalTrials.gov registry entry for NCT03335072 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 320,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 565-participant average among 4 other Trachoma trials with a reported enrollment target (56537% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Trachoma appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.

NCT03335072 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Other.

Frequently Asked Questions

What is clinical trial NCT03335072 about?

NCT03335072 is a clinical study titled "Kebele Elimination of Trachoma for Ocular Health". The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution...

What is the current status of trial NCT03335072?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 320,000 participants. The study started on 2022-02-07. Estimated completion is 2028-03-01.

What conditions does trial NCT03335072 study?

This clinical trial studies the following conditions: Trachoma.

What interventions are being tested in trial NCT03335072?

The interventions under investigation include: Azithromycin (DRUG).

Who is sponsoring clinical trial NCT03335072?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03335072 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trachoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.